Study S000464

Tolerability of Cagrilintide in People With Obesity That Discontinued GLP-1-RA Therapies Due to Gastrointestinal Adverse Events: a Double-blinded Randomised Feasibility Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07607587
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 114
Start: 2026-05-29
Primary completion: 2027-11-19
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity; Overweight
Interventions: DRUG:Cagrilintide; DRUG:Placebo (matched to Cagrilintide)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1325-8511

Registered primary outcomes

Percentage of participants on standard dose or higher dose (yes/no) of cagrilintide and placebo [At week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.